Clinical trial
Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer
NCT00268151 is registered in ClinicalTrials.gov with University of Louisville as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer
- Lead sponsor
- University of Louisville
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 28, 2005
- Completion date
- Not reported
- Enrollment
- 24
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, non-small cell lung